Suppressive Effect of Captopril on Platelet Aggregation in Essential Hypertension

Abstract
Captopril effects on platelet aggregation were studied in 12 essential hypertensive subjects. Also, the effects of captopril and angiotensin II on platelet aggregation in vitro were examined in 20 volunteers. A 50-mg of captopril was administered orally and daily to hypertensive subjects for 2 wk; the dose increased to 100 mg daily for 2 wk. Values of platelet aggregation induced by ADP, epinephrine, collagen and arachidonic acid before captopril treatment were 71.9 .+-. 4.5, 77.3 .+-. 4.2, 72.4 .+-. 4.1 and 70.8 .+-. 4.3% (mean .+-. SE), respectively. After 2 wk of daily administration of 50 mg captopril, these values were 56.7 .+-. 4.5, 50.8 .+-. 7.6, 64.0 .+-. 4.6 and 60.9 .+-. 3.9%, respectively, with significant reduction of platelet aggregation (P < 0.001, P < 0.01, P < 0.01 and P < 0.005, respectively). Captopril (100 mg) administred daily also had a significant suppressive effect on platelet aggregation. Platelet count changes and serum lipids were not significant. In vitro, captopril and angiotensin II added to platelet-rich plasma had no effect on platelet aggregation. The suppressive effect of captopril on platelet aggregation evidently is a secondary action in vivo.

This publication has 1 reference indexed in Scilit: